- Home
- ARCT
as 12-18-2024 9:46am EST
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 602.7M | IPO Year: | N/A |
| Target Price: | $65.00 | AVG Volume (30 days): | 380.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.93 - $45.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | $160,399,000 | Revenue Growth: | -45.85% |
| Revenue Growth (this year): | 6.91% | Revenue Growth (next year): | 5.24% |
Stock Insider Trading Activity of Arcturus Therapeutics Holdings Inc. (ARCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Oct 15 '24 | Sell | $20.76 | 12,000 | $249,121.20 | 435,334 |
Latest Arcturus Therapeutics Holdings Inc. News
ARCT Breaking Stock News: Dive into ARCT Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
7 days ago
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers
Business Wire
22 days ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Business Wire
a month ago
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Business Wire
a month ago
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
MT Newswires
a month ago
Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial
Business Wire
a month ago
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Simply Wall St.
a month ago
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations
Compare ARCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARCT Arcturus Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.